Sandrini G, Alfonsi E, De Rysky C, Marini S, Facchinetti F, Nappi G
Eur J Pharmacol. 1986 Nov 4;130(3):311-4. doi: 10.1016/0014-2999(86)90283-9.
The possible analgesic activity of ritanserin (a new very selective and potent serotonin-S2 antagonist) was studied (double-blind) in humans. A significant increase in nociceptive flexion reflex threshold and subjective pain threshold was observed after five days of treatment, while treatment with placebo did not induce any change. The effects of ritanserin were not reversed by either naloxone or saline (double-blind) administration. Our data suggest a possible role of serotonin-S2 receptors in analgesia.
对新型高选择性强效5-羟色胺-S2拮抗剂利坦色林的潜在镇痛活性进行了人体双盲研究。治疗五天后，伤害性屈曲反射阈值和主观疼痛阈值显著提高，而安慰剂治疗未引起任何变化。利坦色林的作用不会因纳洛酮或生理盐水双盲给药而逆转。我们的数据表明5-羟色胺-S2受体在镇痛中可能发挥作用。
